The DOI matches its Crossref record.
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Abstract
Previous studies have shown that vascular endothelial growth factor (VEGF) promotes progression in epithelial ovarian cancer and that blockade of VEGF inhibits growth of this tumor and metastasis. Bevacizumab is a humanized anti-VEGF monoclonal antibody that has single-agent activity in women with recurrent ovarian tumors. This multinational double-blind placebo-controlled trial was designed to evaluate the addition of bevacizumab to standard front-line ovarian cancer therapy in patients with stage III or IV epithelial ovarian cancer. All eligible patients with previously untreated incompletely resectable stage III or any stage IV epithelial ovarian cancer after maximal debulking surgery were randomized to 1 of 3 groups (control, bevacizumab-initiation treatment, and bevacizumab-throughout treatment). Each of the 3 regimens was composed of 22 three-week cycles, with intravenous infusions during first 6 cycles of both carboplatin at an area under the curve of 6 and paclitaxel at a dose of 175 mg/m2 of body-surface area (carboplatin and paclitaxel (CP) therapy). The control group received CP therapy with placebo added in cycles 2 through 22; bevacizumab-initiation group received CP therapy with addition of bevacizumab (15 mg/kg body weight) in cycles 2 through 6 and placebo in cycles 7 through 22; and the bevacizumab-throughout group received CP therapy with addition of bevacizumab (15 mg/kg body weight) in cycles 2 through 22. Progression-free survival according to treatment group was the primary study end point. A total of 1873 women were enrolled from 336 institutions in 4 countries. Analysis of progression-free survival showed mean survival of 10.3 months in the control group, 11.2 in the bevacizumab-initiation group, and 14.1 in the bevacizumab-throughout group. Compared with the control group, there was a lower, but statistically nonsignificant, decrease in the hazard of progression or death in the bevacizumab-initiation group (hazard ratio, 0.908; 95% confidence interval, 0.795–1.040; P = 0.16). In contrast, the hazard was significantly lower in the bevacizumab-throughout group (hazard ratio, 0.717; 95% confidence interval, 0.625–0.824; P < 0.001). At the time of the primary analysis, 76.3% of patients were alive, with no significant differences in overall survival between groups. Hypertension of grade 2 or higher that required medical intervention was significantly more common in the bevacizumab-initiation group (16.5%) and the bevacizumab-throughout group (22.9%) compared with the control group (7.2%) (P < 0.05 for both comparisons). Gastrointestinal wall disruption requiring medical therapy occurred in 2.8% of patients in the bevacizumab-initiation group, 2.6% in the bevacizumab-throughout group, and 1.2% of patients in the control group. These findings show that addition of bevacizumab during and up to 10 months after CP therapy prolongs the median progression-free survival by 4 months in patients with advanced ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,172
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,883
Aghajanian, C., Blank, S. V., Goff, B. A., Judson, P. L., Teneriello, M. G., Husain, A., Sovak, M. A., Yi, J., & Nycum, L. R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.0505 · Cited by 1,384
Oza, A. M., Cook, A. D., Pfisterer, J., Embleton, A., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00086-8 · Cited by 875
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer
Welti, J., Loges, S., Dimmeler, S., & Carmeliet, P. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70212 · Cited by 591
Metadata
- Authors
- Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., Boente, M., Birrer, M. J., & Liang, S. X.
- Venue
- Obstetrical & Gynecological Survey
- Published
- 2012-05
- Volume
- 67
- Issue
- 5
- Pages
- 289-290
- ISSN
- 0029-7828 (ISSN-L)
- OpenAlex
- W2329128549
- Cited by
- 244
- References
- 0
- FWCI
- 64.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. https://app.cochat.ai/papers/10.1097/ogx.0b013e3182547170
- The paper
- Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., Boente, M., Birrer, M. J., & Liang, S. X. (2012). Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. Obstetrical & Gynecological Survey. https://doi.org/10.1097/ogx.0b013e3182547170
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.